Webcasts: AABB Baltimore 2010 Workshop

Making blood safety decisions in the face of uncertainty
Considering the potential role of pathogen inactivation as protection against XMRV and future emerging pathogens Presented on Tuesday, October 12 • Baltimore, MD
In association with the AABB Annual Meeting & CTTXPO 2010
Overview
This presentation explores the challenges faced by healthcare decision makers and blood centers in times of broad public concern about a new emerging pathogen. The ongoing controversy surrounding the incidence and disease association of XMRV and MLV-related viruses provides a current example of definitive data. The possible role that pathogen inactivation (PI) can play as a defense against emerging pathogens is discussed.
speaker header

castro

Emma Castro, MD
Medical Director & CEO
Spanish Red Cross Transfusion Center, Madrid, Spain

Dr. Castro earned her medical degree at La Laguna University and Hospital Aranzazu (Donostia) where she completed her residency in Haematology and Haemotherapy. For nine years she was director of the blood bank of the Hospital del Pino (Canary Islands) and since 1995 she has been the Medical Director and CEO of the Spanish Red Cross Blood Center in Madrid. She has also been an advisor to WHO and serves as Secretary of the Working Party of Transfusion Transmitted Infectious Diseases of the ISBT. She has published more than 200 abstracts and 20 original articles in medical journals.
katz

Louis M. Katz, MD
Executive Vice President, Medical Affairs
Mississippi Valley Regional Blood Center, Davenport, Iowa, USA

Dr. Katz trained in internal medicine and infectious diseases at the University of Iowa Hospitals and Clinics. From 1982 through 2009 he was engaged in critical care infectious diseases and clinical virology, hospital epidemiology, blood banking and public health. He is now the full time Executive Vice President, Medical Affairs at MVRBC in Davenport, Iowa. Dr. Katz has served as the chair of the ABC Scientific, Medical, and Technical Committee, as a member and chair of the FDA Blood Products Advisory Committee, and incoming chair of AABB’s Transfusion
Transmitted Diseases Committee.
reed

William F. Reed, MD
Director, Clinical Research & Medical Affairs
Cerus Corporation, Concord, CA, USA

Dr. Reed received his medical degree from Brown University. He has been a faculty member at the University of California San Francisco School of Medicine and served as Medical Director for the Northern California Region of the American Red Cross. Prior to joining Cerus in late 2009, he was an investigator for ten years at Blood Systems Research Institute in San Francisco. His research interests include hemoglobinopathies, placental blood banking & transplantation and leukocyte microchimerism following transfusion.